Early treatment with Jakafi (ruxolitinib) is no better than older therapies at inducing a complete response in those with polycythemia vera (PV), but it…
News
The European Commission has cleared Tecvayli (teclistamab-cqyv) as a monotherapy, meaning it can be given on its own, for adults whose myeloma returned or…
Changes in blood levels of an enzyme called lactate dehydrogenase (LDH) may offer clues about disease activity in glioblastoma, an aggressive type of glioma,…
The International Myeloma Foundation has started a first-of-its-kind national clinical research network aiming to expand access to clinical trials and improve care for people…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the investigational therapy onvansertib as a potential treatment for chronic myelomonocytic leukemia…
An approved treatment regimen using the oral therapy Zenbexus (iberdomide) can reduce the risk of disease progression among people with hard-to-treat multiple myeloma,…
PANCREATIC CANCER
Experimental enzyme treatment reduces tumor growth in cancer study
An experimental therapy containing a specific ratio of two naturally occurring pancreatic enzymes may be able to reduce the growth of certain cancers, including…
An arm of the European Medicines Agency (EMA) — which reviews clinical trial data for drugs under regulatory review in the European Union — has…
ACUTE MYELOID LEUKEMIA
First-in-human trial launches in US to test drug for hard-to-treat AML
A first-in-human clinical trial testing Orum Therapeutics‘ infusion therapy ORM-1153 in people with hard-to-treat acute myeloid leukemia (AML), a form of blood cancer, has…
A new study by U.S. researchers suggests that using high-potency chemotherapy in myeloma as part of bridging therapy — medications given before patients are…
Recent Posts
- Trial finds treatment eases PV symptoms despite missing main goal
- The quiet courage of taking a short break as a caregiver
- EU clears Tecvayli as solo option when myeloma returns after first treatment
- Blood marker changes may help track glioblastoma progression
- Social media can be a scary place for myeloma patients